These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38833091)

  • 1. The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience.
    Kozak I; Gurbaxani A; Pandova M
    J Ophthalmic Inflamm Infect; 2024 Jun; 14(1):24. PubMed ID: 38833091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months.
    Moll-Udina A; Hernanz I; Sainz-de-la-Maza M; Pelegrín L; Coelho-Borges AI; Pazos M; Adán A; Llorenç V
    Int Ophthalmol; 2023 Nov; 43(11):4181-4195. PubMed ID: 37698661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of 0.19 mg Fluocinolone Acetonide Implant in Non-infectious Posterior Uveitis Evaluated as Area Under the Curve.
    Battista M; Starace V; Cicinelli MV; Capone L; Marchese A; Modorati G; Bandello F; Miserocchi E
    Ophthalmol Ther; 2022 Feb; 11(1):215-224. PubMed ID: 34787827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis.
    Hikal M; Celik N; Auffarth GU; Kessler LJ; Mayer CS; Khoramnia R
    J Clin Med; 2021 Sep; 10(17):. PubMed ID: 34501414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations.
    Pleyer U; Pavesio C; Miserocchi E; Heinz C; Devonport H; Llorenç V; Burke T; Nogueira V; Kodjikian L; Bodaghi B
    J Ophthalmic Inflamm Infect; 2024 May; 14(1):22. PubMed ID: 38814386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
    Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
    Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India.
    Biswas J; Tyagi M; Agarwal M;
    Ophthalmol Sci; 2024; 4(1):100403. PubMed ID: 38027419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
    El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
    Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN
    Bodaghi B; Nguyen QD; Jaffe G; Khoramnia R; Pavesio C
    J Ophthalmic Inflamm Infect; 2020 Nov; 10(1):32. PubMed ID: 33251553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre.
    Pockar S; Leal I; Chhabra R; Jones NP; Steeples LR
    Ocul Immunol Inflamm; 2023 Oct; 31(8):1572-1578. PubMed ID: 34124978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE.
    Elbarky AM
    Clin Ophthalmol; 2020; 14():823-830. PubMed ID: 32214793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Experience of Fluocinolone Acetonide 0.19 mg in the Management of Non-Infectious Uveitis.
    Logeswaran A; Azzopardi M; Demir B; D'Alonzo G; Chong YJ; Addison P; Pavesio C
    Ocul Immunol Inflamm; 2024 Jul; ():1-6. PubMed ID: 39042811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of 0.19-mg Fluocinolone Acetonide Implant in Postoperative Cystoid Macular Edema after Pars Plana Vitrectomy: the ILUCYD study.
    Motloch K; Soler V; Delyfer MN; Vasseur V; Wolff B; Issa M; Dot C; Massé H; Weber M; Comet A; Hitzl W; Matonti F; Creuzot-Garcher C; Tadayoni R; Kodjikian L; Couturier A
    Ophthalmol Retina; 2024 Jul; ():. PubMed ID: 39004282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center.
    Abu Arif J; Knecht VA; Rübsam A; Lussac V; Jami Z; Pohlmann D; Müller B; Pleyer U
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38791073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 18. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema.
    Weber LF; Marx S; Auffarth GU; Scheuerle AF; Tandogan T; Mayer C; Khoramnia R
    J Ophthalmic Inflamm Infect; 2019 Jan; 9(1):3. PubMed ID: 30694420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis.
    Pavesio C; Heinz C
    Eye (Lond); 2022 Jun; 36(6):1231-1237. PubMed ID: 34117380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study.
    Buhl L; Thurau S; Kern C
    Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1101-1108. PubMed ID: 36399176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.